Antibiotics in severely malnourished children: systematic review of efficacy, safety and pharmacokinetics

593Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Abstracts in بيرع, 中文, Français, Pусский and Español at the end of each article. Antibiotics in severely malnourished children: systematic review of efficacy, safety and pharmacokinetics Marzia Lazzerinia & David Tickellb Introduction Malnutrition is a major health problem in low- and middle- income countries, particularly in children less than 5 years of age. Recent estimates suggest that 3.5% of children worldwide, or nearly 20 million, are severely malnourished.1 Severe acute malnutrition (SAM), characterized by a weight of less than 70% of the median weight for height and/or bipedal oedema, is a life-threatening condition.2,3 In the absence of appropriate treatment, case-fatality rates in hospitalized children range from 30% to 50%.1,4 In 1999 the World Health Organization (WHO) pub- lished Management of severe malnutrition: a manual for physi- cians and other senior health workers2 to update its 1981 guide- lines. A chapter on SAM is also included in the 1995 WHO Pocketbook of hospital care for children.3 Both guidelines focus on hospitalized children. Given recent advances with ready-to- use therapeutic foods, WHO, the United Nations Children’s Fund, the United Nations World Food Programme and the United Nations Standing Committee on Nutrition released a 2007 statement supporting the community treatment of severe malnutrition. The statement focuses on the outpatient manage- ment of children with SAM and no medical complications.5 Uncomplicated SAM is defined as a weight of greater than 60% of the median weight for height without marasmic kwashiorkor or severe pitting oedema in children older than 6 months, and without anorexia, fever, hypothermia, vomiting, severe dehydra- tion, severe anaemia, altered consciousness, altered respiration or moderate to severe skin infections. Since their publication, the WHO guidelines for the hos- pital treatment of children with SAM have been implemented in many countries worldwide. A recent systematic review high- lighted that their implementation has resulted in half of the in-hospital mortality observed with conventional treatment.4 Despite these guidelines, SAM-related mortality remains high in many settings primarily because of operational hin- drances to correct guideline implementation6,7 and because the affected population has changed as a result of the epidemic of human immunodeficiency virus (HIV) in many countries. A recent systematic review of 17 studies (4891 children) reported that, despite treatment for malnutrition, malnourished children who are HIV-positive (HIV+) are significantly more likely to die than malnourished children who are HIV-negative (HIV−) (30.4% versus 8.4%, respectively; P < 0.001; relative risk, RR: 2.81).8 Other factors, such as changing patterns of susceptibility to antibiotics, may also explain the reduced effectiveness of the guidelines in some contexts. The WHO guidelines for the hospital treatment of children with SAM include a sequence of 10 fundamental steps. We focus this review on WHO’s recommendations for antibiotic treatment (Box 1).2,3 Rationale for antibiotics in severely malnourished children Several epidemiological studies have documented a high preva- lence of pneumonia, bacteraemia and urinary tract infections in children with malnutrition (Table 1).9–23 In this cohort a wide range of both Gram-positive and Gram-negative organisms are Objective To systemically review the evidence in support of World Health Organization guidelines recommending broad-spectrum antibiotics for children with severe acute malnutrition (SAM). Methods CENTRAL, MEDLINE, EMBASE, LILACS, POPLINE, CAB Abstracts and ongoing trials registers were searched. Experts were contacted. Conference proceedings and reference lists were manually searched. All study types, except single case reports, were included. Findings Two randomized controlled trials (RCTs), one before-and-after study and two retrospective reports on clinical efficacy and safety were retrieved, together with 18 pharmacokinetic studies. Trial quality was generally poor and results could not be pooled due to heterogeneity. Oral amoxicillin for 5 days was as effective as intramuscular ceftriaxone for 2 days (1 RCT). For uncomplicated SAM, amoxicillin showed no benefit over placebo (1 retrospective study). The introduction of a standardized regimen using ampicillin and gentamicin significantly reduced mortality in hospitalized children (odds ratio, OR: 4.0; 95% confidence interval, CI: 1.7–9.8; 1 before- and-after study). Oral chloramphenicol was as effective as trimethoprim-sulfamethoxazole in children with pneumonia (1 RCT). Pharmacokinetic data suggest that normal doses of penicillins, cotrimoxazole and gentamicin are safe in malnourished children, while the dose or frequency of chloramphenicol requires adjustment. Existing evidence is not strong enough to further clarify recommendations for antibiotic treatment in children with SAM. Conclusion Large RCTs are needed to define optimal antibiotic treatment in children with SAM with and without complications. Further research into gentamicin and chloramphenicol toxicity and into the pharmacokinetics of ceftriaxone and ciprofloxacin is also required. a Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. b Centre for International Child Health, Royal Children’s Hospital, Melbourne, Vic., 3052 Australia. Correspondence to David Tickell (e-mail: davetickell@yahoo.com.au). (Submitted: 21 November 2010 – Revised version received: 31 March 2011 – Accepted: 8 April 2011 – Published online: 20 May 2011 ) Systematic reviews 594 Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished children Marzia Lazzerini & David Tickell frequently isolated,9–23 which supports the recommendation of a broad spectrum antibiotic for these children.2,3 Pathogen prevalence and the risk of infection in children with uncomplicated SAM treated in the community is still not clear. It is also uncertain whether infection rates and types are different in HIV+ and HIV− children.10–13 Patterns of susceptibility to antibi- otics vary between countries, although high rates of in vitro resistance to am- picillin and cotrimoxazole, as reported in several African countries, are causing general concern.10–15 High rates of re- sistance to second-line antibiotics such as chloramphenicol, gentamicin and cephalosporins have also been reported in selected contexts,12–15 while in general, sensitivity to ciprofloxacin remains high (Table 1).9–23 In vitro resistance, however, does not necessarily translate into lack of clinical efficacy. The objective of this review is to examine studies evaluating the efficacy, safety and pharmacokinetics (PK) of antibiotics in children with severe acute malnutrition (SAM). This review was commissioned by WHO’s Department of Essential Medicines and Pharmaceuti- cal Policies to assess the existing evidence behind current WHO antibiotic recom- mendations for the management of SAM, allowing further revision of guidelines and recommendations for future research. To our knowledge, no other systematic reviews addressing this specific question have been published. Methods Two authors independently reviewed data on pharmacokinetics and clinical efficacy and safety. Both authors collaborated on and cross-checked extracted data, analysis of results and final recommendations. We wrote a protocol of our methods that was externally reviewed before we searched and summarized the data. Our inclusion criteria were as follows: (i) any study type that reported patient out- comes except single case reports; (ii) for clinical studies, only children under 12 years of age, and for pharmacokinetic studies, adults as well; (iii) as antibiotics, amoxicillin, ampicillin, cotrimoxazole, gentamicin, penicillin G, chlorampheni- col, ceftriaxone and ciprofloxacin; as a control in controlled trials, placebo or active treatment; as predefined outcomes, death, recovery, weight gain, prevention of septic shock and adverse events. We searched CENTRAL, MED- LINE, EMBASE, LILACS, POPLINE and CAB Abstracts to retrieve relevant studies published between 1951 and September 2010 regardless of language, publication status or study type (Box 2). For ongoing trials, we also accessed the WHO International Clinical Trials Reg- istry Platform, metaRegister of Current Controlled Trials, Clinical trial.gov, the European register of clinical trials on medicines for children and the Lancet’s list of accepted protocols. We contacted experts in the field and manually searched presentations from relevant conferences, reports and the reference lists of the stud- ies identified. We used standard textbooks as references for pharmacokinetic data in eutrophic children.24,25 Data collection and analysis We scrutinized every paper to avoid du- plication and assessed the full text of all potentially relevant trials. To extract the data we used a predefined form. Study heterogeneity in intervention population and design prevented us from pooling the results. These are shown in tables and in the text. We used Cochrane criteria to assess the risk of bias (quality) in the clinical studies. Results Study selection is reported in Fig. 1. Al- though we found 2100 studies in broad sensitive searches, only 23 were suitable for inclusion. Studies were excluded because either they lacked relevance to the question, were duplicated, were case reports or animal studies, studied inap- propriate populations or had a poor trial design. Table 2 shows the characteristics of clinical studies and the overall risk of bias in each study.21,26–29 Characteristics of pharmacokinetic studies are detailed in Table 3, Table 4 and Table 5.30–48 All included studies refer to children with SAM unless otherwise stated. Amoxicillin Clinical safety and efficacy Two studies were retrieved: one was a randomized controlled trial (RCT) and the other a retrospective study (n = 458 and n = 2453, respectively). In the RCT, no significant differences in any of the ef- ficacy outcomes were found in children with SAM who received oral amoxicillin for 5 days versus intramuscular ceftriax- one for 2 days. Adverse events were more frequent in the amoxicillin group (eight drug reactions versus two; P = 0.05). No local infections or pain after intramuscu- lar ceftriaxone injection were observed. The costs of treating one child weighing 10 kg were 1.60 United States dollars (US$) for ceftriaxone versus US$ 0.20 for amoxicillin.27 In the retrospective study, which compared oral amoxicillin for 7 days to no antibiotics, children with uncompli- cated SAM who received amoxicillin had a lower recovery rate (39.8%) than untreated children (70.8%) (P < 0.001) at 4 weeks but a similar rate of recovery at 12 weeks, and similar rates of death and default.26 One ongoing RCT is exploring the efficacy of amoxicillin versus cefdinir versus no treatment in children with Box 1. WHO guidelines for the management of children with severe acute malnutrition2,3 • If the child appears to have no complications, give: cotrimoxazole for 5 days (20 mg of sulfamethoxazole + 4 mg of trimethoprim per kilogram orally twice daily). A short course of oral antibiotics is also advised for children with uncomplicated SAM treated in the community.5 • If there are complications give: ampicillin (25–50 mg/kg IM/IV 6-hourly for 2 days), then oral amoxicillin (15 mg/kg 8-hourly for 5 days) OR, if amoxicillin is not available, oral ampicillin (25–50 mg/kg 6-hourly for 5 days) over a total of 7 days AND gentamicin (7.5 mg/kg IM/IV) once daily for 7 days. • If the child fails to improve within 48 hours: add chloramphenicol (25 mg/kg IM/IV 8-hourly) for 5 days. • If meningitis is suspected: do a lumbar puncture for confirmation, where possible, and treat with chloramphenicol (25 mg/kg 6 hourly) for 10 days. • If other specific infections are identified (such as pneumonia, dysentery, skin- or soft-tissue infections): give antibiotics as appropriate. Antimicrobials should be continued for at least 5 days. The duration of treatment depends on the response and nutritional status of the child. If anorexia still persists after 5 days of treatment, give the child another 5-day course. The regimens should be adapted depending on local resistance patterns. IM, intramuscular; IV, intravenous 595Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished childrenMarzia Lazzerini & David Tickell Ta bl e 1. I nc id en ce o f b ac te ria l i nf ec tio ns in c hi ld re n w ith s ev er e ac ut e m al nu tr iti on Ye ar Co un tr y No . o f ch ild re n (% HI V+ ) Gr ad e of m al nu tr iti on Ba ct er ae m ia (% ) LR TI (% ) UT I (% ) Is ol at ed b ac te ria An tib io tic re si st an ce in v itr oa TM P- SM X Cl av ul Am pi Ge nt a CA F Ce ph Ci pr o 20 06 Un ite d Re pu bl ic o f Ta nz an ia 9 78 1 (1 9) Se ve re 3 17 8 NR 20 06 Ke ny a9 34 0 (9 ) Se ve re 5 7 – NR 20 06 Ug an da 10 45 0 (3 6) Se ve re 17 – – Sa lm on el la ty ph im ur iu m , St ap hy lo co cc us a ur eu s, Sa lm on el la en te rit id is, S tre pt oc oc cu s pn eu m on ia e + + + + + + + 20 06 Ug an da 11 31 5 (3 9) Se ve re 18 68 26 NR 20 06 Ug an da 12 13 4 (4 4) Se ve re 22 – – Sa lm on el la s pp , E sc he ric hi a co li + + + + + + + + + + 20 05 Ke ny a1 3 91 (4 3) Se ve re 29 – Co ag ul as e- ne ga tiv e st ap hy lo co cc i + + + + + + + + 20 02 Ni ge ria 14 19 4 (N R) Se ve re – – 11 .3 Es ch er ich ia c ol i, Kl eb sie lla s pp , Ps eu do m on as s pp + + + + + + + + + /+ + + 20 01 Co ng o1 5 Un cl ea r Se ve re 13 .2 – – En te ro ba ct er ia ce ae + + + + + + 20 01 Ja m ai ca 16 15 0 (N R) M od -s ev er e 10 – – Co ag ul as e- ne ga tiv e st ap hy lo co cc i + + + 20 00 M al aw i17 75 (2 5) Se ve re 9 – 17 St re pt oc oc cu s pn eu m on ia e, K le bs ie lla sp p, E sc he ric hi a co li 20 00 Tu rk ey 18 10 3 (N R) Al l – – 31 Es ch er ich ia c ol i, Kl eb sie lla s pp , Pr ot eu s sp p + + + + + 19 96 So ut h Af ric a1 9 32 3 (N R) Se ve re 9. 6 – – Gr am -n eg at ive e nt er ic b ac illi 19 95 So ut h Af ric a2 0 13 4 (N R) Se ve re – – 26 Gr am -n eg at ive e nt er ic b ac illi 19 94 Ga m bi a2 1 37 8b (N R) Al l – 28 – St re pt oc oc cu s pn eu m on ia e, Ha em op hi lu s sp p 19 92 So ut h Af ric a2 2 13 4 (N R) NR – – 26 NR 19 92 Un ite d Re pu bl ic o f Ta nz an ia 23 16 4 (N R) Se ve re In fe ct io ns a t a dm is si on : 9 2% In -h os pi ta l i nf ec tio ns : 4 9% St ap hy lo co cc us a ur eu s, Es ch er ich ia co li, Kl eb si el la s pp , E nt er oc oc cu s fa ec al is, E sc he ric hi a co li Am pi , a m pi ci llin ; C AF , c hl or am ph en ic ol ; C ep h, c ep ha lo sp or in (c ef tri ax on e; c ef ot ax im e, c ef ta zid im e) ; C ip ro , c ip ro flo xa ci n; C la vu l, am ox ic illi n an d cl av ul an ic a ci d; G en ta , g en ta m ic in ; L RT I, lo w er re sp ira to ry tr ac t i nf ec tio n; N R, n ot re po rte d; s pp , sp ec ie s; T M P- SM X, c or im ox az ol e; U TI , u rin ar y tra ct in fe ct io n. a + > 2 0% ; + + > 5 0% ; + + + > 7 5% . b C hi ld re n w ith p ne um on ia . 596 Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished children Marzia Lazzerini & David Tickell uncomplicated SAM (Trial identifier NCT01000298). Pharmacokinetics Three small studies reported on the pharmacokinetics of oral penicillins (Table 3).30–32 The oral bioavailability of penicillin V was the same regardless of nutritional status, although it was significantly reduced when the drug was taken with food.30 Time to maximum concentration (Cmax) of amoxicillin was significantly longer in children with kwashiorkor31 and time to Cmax of penicil- lin V was longer, though not significantly, in all malnourished groups.30 However, all malnourished subjects attained high enough serum levels for clinical effect to Box 2. Search strategy for databases of published studies on the use of antibiotics in children with severe acute malnutrition Search strategya for MEDLINE, adapted for otherb searches • Amoxicillin OR ampicillin OR penicillin OR procaine penicillin • AMOXICILLIN+ OR AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION OR AMPICILLIN+ OR PENICILLINS+ OR PENICILLIN G+ OR PENICILLIN G, PROCAINE • Gentamicin OR aminoglycoside OR GENTAMICINS+ • Cotrimoxazole OR sulfamethoxazole OR sulfamethoxazole OR trimethoprim OR TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION • Ceftriaxone OR cephalosporin OR CEFTRIAXONE+ • Ciprofloxacin OR quinolone OR fluoroquinolone OR CIPROFLOXACIN+ • Chloramphenicol OR CHLORAMPHENICOL+ • OR/1–7 • Malnutrition OR malnourished OR underweight OR kwashiorkor OR marasmus • MALNUTRITION OR PROTEIN-ENERGY MALNUTRITION OR CHILD NUTRITION DISORDERS OR INFANT NUTRITION DISORDERS • OR/9–10 • Pharmacokinetic OR action OR effect OR absorption OR distribution OR clearance OR metabolism • PHARMACOKINETICS+ • OR/12–13 • 8 AND 11 • 8 AND 11 AND 14 (for pharmacokinetic studies) • Limit 15 to human (for clinical safety and efficacy trials) a Upper case: MeSH or EMTREE heading; lower case: free text term; +: exploded term. b CENTRAL, EMBASE, LILACS, POPLINE and CAB Abstracts. Fig. 1. Flowcharts for bibliographic search of studies on the use of antibiotics in children with severe acute malnutrition Clinical and efficacy studies retrieved in electronic databases and ongoing trials: 464 Additional studies: Writing to experts: 5 Manual search: 0 Reference: 5 Total retrieved studies: 474 Excluded studies: 469 Included studies: 2 RCTs 1 before-and-after trial 2 retrospective reports Pharmacokinetic studies retrieved in electronic databases and ongoing trials: 2056 Additional studies: Writing to experts: 1 Manual search: 0 Reference: 2 Total retrieved studies: 2059 Excluded studies: 2041 Included studies: 18 RCT, randomized controlled trial. 597Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished childrenMarzia Lazzerini & David Tickell Ta bl e 2. S tu di es o n ef fic ac y an d sa fe ty o f a nt ib io tic s in c hi ld re n w ith s ev er e ac ut e m al nu tr iti on Re fe re nc e De si gn (R is k of b ia s) Po pu la tio n In te rv en tio n gr ou ps Ou tc om es Gr ou p 1 n (% ) Gr ou p 2 n (% ) Tr eh an e t a l. 20 10 26 – Re tro sp ec tiv e (h ig h) – Se tti ng : M al aw i – Ye ar s: 2 00 3– 20 05 (n = 2 4 53 ) – In cl us io n cr ite ria : a ge 6 –5 9 m on th s, no c om pl ic at io ns – Ex cl us io n cr ite ria : p oo r a pp et ite , al te re d m en ta l s ta tu s, lo w p er fu si on o r re sp ira to ry d is tre ss 1. A m ox ic illi n 60 m g/ kg /d ay , 7 d ay s 2. N ot hi ng Re co ve re d at 4 w ee ks Re co ve re d at 1 2 w ee ks Di ed a t 4 w ee ks Di ed a t 1 2 w ee ks De fa ul te d at 4 w ee ks De fa ul te d at 1 2 w ee ks 19 8 (3 9. 8) 41 7 (8 3. 7) 10 (2 ) 13 (2 .6 ) 26 (5 .2 ) 39 (7 .8 ) 13 85 (7 0. 8) * 1 67 3 (8 5. 6) 26 (1 .3 ) 34 (1 .7 ) 12 1 (6 .2 ) 18 2 (9 .3 ) Du br ay e t a l. 20 08 27 – RC T (lo w ) – Se tti ng : S ud an – Ye ar s: 2 00 2– 20 03 (n = 4 58 ) – In cl us io n cr ite ria : a ge 6 –5 9 m on th s – Ex cl us io n cr ite ria : r ef us e, s tu dy d ru gs in th e 7 da ys b ef or e, h yp er se ns iti vit y, us ed a d iff er en t d ru g, v om iti ng , co nv ul si on , i m pa ire d co ns ci ou sn es s, ot iti s 1. C ef tri ax on e 75 m g/ kg o nc e da ily IM , 2 d ay s 2. A m ox ic illi n 40 m g/ kg tw ic e da ily o ra l, 5 da ys W G > 1 0 g/ kg /d ay (I TT ) W G > 1 0 g/ kg /d ay (P P) Re co ve re d Di ed De fa ul te d Re fe rre d Le ng th o f s ta y (d ay s) Ad ve rs e ev en t 12 3 (5 3. 5) 89 (6 3. 1) 16 1 (7 0) 9 (3 .9 ) 39 (1 7) 4 (1 .7 ) 33 .5 8 (4 ) 12 7 (5 5. 7) 88 (6 2. 9) 17 0 (7 4. 6) 7 (3 .1 ) 43 (1 8. 9) 2 (0 .9 ) 31 .4 2 (1 )* W ilk in so n et a l. 19 96 28 – Pr e an d af te r s tu dy (h ig h) – Se tti ng : S ou th A fri ca – Ye ar s: 1 99 2– 19 93 (n = 3 00 ) – In cl us io n cr ite ria : h os pi ta liz ed – Ex cl us io n cr ite ria : n ot re po rte d 1. N o st an da rd re gi m en (W at er lo w p ro to co l 1 99 3) 2. A m pi ci llin (7 d ay s or al ly, IV fo r s ic k ch ild re n) Ge nt am ic in (5 d ay s IM ), Gl yc ae m ia c on tro ls De at h 32 (2 0) 8 (6 )* M ul ho lla nd e t a l. 19 95 21 – RC T (m ed iu m ) – Se tti ng : G am bi a – Ye ar s: 1 99 0– 19 92 (n = 1 44 ) – In cl us io n cr ite ria : a ge d < 5 y ea rs , ra di ol og ic al e vid en ce o f p ne um on ia 1. C hl or am ph en ic ol 2 5 m g/ kg 8 -h ou rly o ra l 2. T M P- SM X 40 /2 00 m g tw ic e da ily (< 1 y ea r ol d) , 6 0/ 30 0m g tw ic e da ily (> 1 y ea r o ld ) Re co ve re d Im pr ov ed Fa ilu re Di ed 21 (2 8) 19 (2 7) 16 (2 6) 4 (5 .4 ) 20 (2 8) 19 (2 7) 16 (2 6) 8 (1 1. 2) Go ld en e t a l. 20 00 29 – Re tro sp ec tiv e (h ig h) – Se tti ng : 9 c ou nt rie s in S SA (u ns pe ci fie d) – Ye ar s: 1 99 4– 19 97 (n u ns pe ci fie d) – In cl us io n cr ite ria : a ge d 6– 59 m on th s, ad m itt ed to T FC An y an tib io tic o n ad m is si on Ne ga tiv e as so ci at io n (r2 = 0 .3 7; P = 0 .0 02 ) b et w ee n m or ta lit y ra tio (o bs er ve d m or ta lit y di vid ed fo r e xp ec te d m or ta lit y as fo r P ru dh on in de x) a nd a nt ib io tic ra tio (p ro po rti on o f c hi ld re n gi ve n an tib io tic s fro m ad m is si on ). IM , i nt ra m us cu la r; IT T, in te nt io n to tr ea t a na lys is ; P P, pe r p ro to co l a na lys is ; R CT , r an do m ize d co nt ro lle d tri al ; S SA , S ub -S ah ar an A fri ca ; T FC , t he ra pe ut ic fe ed in g ce nt re ; T M P– SM X, tr im et ho pr im -s ul fa m et ho xa zo le ; W G, w ei gh t g ai n; * P < 0 .0 01 . 598 Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished children Marzia Lazzerini & David Tickell Ta bl e 3. P ha rm ac ok in et ic s of fi rs t- lin e or al a nt ib io tic s in c hi ld re n w ith s ev er e ac ut e m al nu tr iti on Re fe r- en ce Dr ug , do se (p er kg ) No . o f c hi l- dr en Ab so rp tio n (% ) C m ax (μ g/ m l) an d T m ax (m in ) Vd (l /k g) p ro te in bi nd in g (% ) Cl ea ra nc e (m l/k g/ h) Ha lf lif e (m in ) AU C (μ g. m in /m l) M al no ur - is he d Eu tr op hi c M al no ur - is he d Eu tr o- ph ic M al no ur - is he d Eu tr op hi c M al no ur - is he d Eu tr o- ph ic M al no ur - is he d Eu tr o- ph ic M al no ur - is he d Eu tr o- ph ic Bo lm e et al . 1 99 53 0 Pe ni ci llin V , 20 m g 47 U (f) : 3 5. 9* U (n f): 29 .8 * M (f ): 66 .1 * M (n f): 22 .7 * K (f) : 8 2. 6* K (n f): 2 7. 1* f: 54 .8 nf : 4 7. 0 U K a (f ): 9. 5* U K a (n f): 3 .9 * M K a ( f): 8 .4 * M K a ( nf ): 0. 8* K K a (f ): 2. 5* K K a (n f): 1 .6 * K a (f ): 10 .1 K a (n f): 2. 2 U (f) : 4 0. 8* U (n f): 6 2. 7* M (f ): 54 .2 * M (n f): 1 45 .2 * K (f) : 1 39 .6 * K (n f): 1 09 .6 * f: 39 .1 nf : 7 5. 6 U (f) : 4 76 .7 * U (n f): 3 96 .0 * M (f ): 94 1. 7* M (n f): 32 3. 2* K (f) : 9 75 .2 * K (n f): 3 19 .5 * f: 49 3. 6 nf : 42 3. 4 Ze rih un e t al . 1 99 13 1 Am ox ic illi n, 25 m g 15 M T m ax : 6 0 K T m ax : 1 20 ** T m ax : 6 0 (a ll gr ou ps a de qu at e C m ax , no v al ue s gi ve n) Bo lm e et al . 1 98 03 2 Pe ni ci llin V , 30 0 00 IU 16 SA M T m ax : 1 20 SA M C m ax : 5 .8 T m ax : 9 0 C m ax : 4 .3 Bu ch an an 19 77 33 Be nz yl- pe ni ci llin , do se N S Ad ul t s er um ve rs us po ol ed se ru m o f 2 4 kw as hi or ko r ch ild re n % fr ee d ru g si m ila r ( N: 59 .1 % , K : 6 4. 0% ) s o Vd lik el y un af fe ct ed TM P- SM X PB : N : 7 1. 9% , K : 93 –9 6% Br av o et al . 1 98 43 4 SM X, 22 m g 17 C m ax : 4 1. 4 T m ax : 1 20 C m ax 3 6. 8 T m ax 1 50 Vd : 0 .5 29 Vd : 0 .5 29 41 83 9. 4 * 4. 9 9. 55 * 5. 47 AU C, a re a un de r t he p la sm a co nc en tra tio n tim e cu rv e; C m ax , m ax im um c on ce nt ra tio n; f, fa st in g; IU , i nt er na tio na l u ni ts ; K , k w as hi or ko r; K a , a bs or pt io n ra te c on st an t; M , m ar as m us ; M K, m ar as m ic k w as hi or ko r; n, n or m al (c on tro ls ); nf , n on -f as tin g; N S, no t s ta te d; P B, p ro te in b in di ng ; S AM , s ev er e ac ut e m al nu tri tio n; S M X, s ul fa m et ho xa zo le ; T m ax , t im e to m ax im um c on ce nt ra tio n; T M P, tri m et ho pr im ; U , u nd er w ei gh t; Vd , v ol um e of d is tri bu tio n; * P < 0 .0 5; * * P- va lu e no t s pe ci fie d. 599Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished childrenMarzia Lazzerini & David Tickell Ta bl e 4. P ha rm ac ok in et ic s of s ec on d- lin e pa re nt er al a nt ib io tic s in c hi ld re n w ith s ev er e ac ut e m al nu tr iti on Re fe re nc e Dr ug , d os e (p er k g) , r ou te No . o f ch il- dr en C m ax (μ g/ m l) an d T m ax (m in ) Vd (l /k g) Cl ea ra nc e (m l/k g/ h) Ha lf lif e (m in ) AU C (μ g. m in /m l) M al no ur is he d Eu tr op hi c M al no ur is he d Eu tr op hi c M al no ur - is he d Eu tr op hi c M al no ur - is he d Eu tr op hi c M al no ur is he d Eu tr op hi c Bo lm e et a l. 19 95 30 Be nz ylp en ic illi n, 30 m g, IV 29 – – U: 1 .4 7 K: 1 .1 8 M : 0 .9 1 M K: 0 .9 3 1. 39 CL U : 1 5. 1* CL K : 1 6. 9* CL M : 1 4. 0* CL M K: 11 .6 * CL 2 2. 2 U: 6 7. 8 K: 4 4. 8 M : 4 4. 8 M K: 5 5. 7 43 .4 U: 1 99 3. 3 K: 1 7 69 .2 M : 2 1 38 .2 M K: 2 5 94 .4 13 51 .3 Pr oc ai ne pe ni ci llin G , 3 0 m g, IM 18 T m ax s am e in a ll gr ou ps (3 0– 60 m in ) – – – – M : 1 39 .1 M K: 2 64 .9 17 7. 4 Sa m e in a ll gr ou ps (n o va lu es gi ve n) Bo lm e et a l. 19 80 32 Be nz ylp en ic illi n, 50 0 00 IU , I V 16 K C m ax a t 2 h : 3 .1 M C m ax a t 2 h : 4. 1 M K C m ax a t 2 h : 10 .2 N C m ax a t 2 h: 1 .4 ** – – Tr en d to sl ow er C L in m al no ur is he d – – – – – Be nz ylp en ic illi n, 16 0 00 IU , I M 13 T m ax < 3 0 m a ll gr ou ps C m ax > 1 0 μg a ll gr ou ps – – Tr en d to sl ow er C L in m al no ur is he d – – – – – Bu ch an an et a l. 19 79 35 Pe ni ci llin G , 25 0 00 IU , I V 8 – – Da y 0: 1 .6 Da y 21 : 1 .4 D0 : 1 83 * D2 1: 2 86 * – D0 : 5 7* D2 1: 3 2* – – – Se at on e t al . 2 00 73 6 Ge nt am ic in , 7 .5 m g, IM 34 10 0% > 8 .0 μ g/ m l a t 2 h ou r 76 % > 1 2. 0 μg / m l a t 2 h ou r – 0. 67 – CL 1 .6 7a Tr ou gh le ve l: 98 % < 1 .0 m g/ l a t 2 0 ha – 84 – – – Sa m ot ra e t al . 1 98 53 7 Ge nt am ic in , 4 .0 m g, IM 10 C m ax 8 .9 a t 3 0 m in C m ax 1 0. 02 at 3 0 m in – – – – 37 3 19 9 22 .4 0 22 .3 2 Kh an e t a l. 20 06 38 Ge nt am ic in , 5 .0 m g, IM 31 0 od : C m ax 1 1. 7 at 60 m in * td s: C m ax 4 .7 a t 60 m in * – – – Tr ou gh le ve l at 2 4 h: od : 0 .2 9 m g/ l* td s: 0 .4 8 m g/ l – – – – – Br av o et a l. 19 82 39 Ge nt am ic in , 3 .5 m g, IV 18 C m ax 6 .3 1 at 29 .6 7 m in * C m ax 8 .3 9 at 2 4 m in 0. 46 * 0. 39 CL 3 .9 9 CL 3 .5 7 82 75 No d iff er en ce (n o va lu es g ive n) Bu ch an an et a l. 19 79 40 Ge nt am ic in , 2 .4 m g, IV 6 – – D0 : 3 .9 D2 1: 4 .3 6* – D0 : C L 13 .6 m l/k g D2 1: C L 28 .7 m l/k g* – D0 : 2 29 D2 1: 1 79 * – – – AU C, a re a un de r t he p la sm a co nc en tra tio n tim e cu rv e; C L, c le ar an ce ; C m ax , m ax im um c on ce nt ra tio n; D 0, d ay 0 (a dm is si on ); D2 1, d ay 2 1 (re co ve ry ); IM , i nt ra m us cu la r; IU , i nt er na tio na l u ni ts ; I V, in tra ve no us ; K , k w as hi or ko r; M , m ar as m us ; M K, m ar as m ic k w as hi or ko r; N, n or m al (c on tro ls ); od , o nc e da ily d os in g; td s, th re e tim es d ai ly do si ng ; T m ax , t im e to m ax im um c on ce nt ra tio n; U , u nd er w ei gh t; Vd , v ol um e of d is tri bu tio n. * P < 0 .0 5; * *P -v al ue n ot s pe ci fie d. a O ne c hi ld w ho w as in s ho ck h ad a tr ou gh le ve l o f 5 .5 μ g/ m l; lo ng er c le ar an ce w as n ot ed in c hi ld re n w ith h yp ot he rm ia , h ig h se ru m c re at in in e or la rg e ba se e xc es s. 600 Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished children Marzia Lazzerini & David Tickell Ta bl e 5. P ha rm ac ok in et ic s of c hl or am ph en ic ol in c hi ld re n w ith s ev er e ac ut e m al nu tr iti on Re fe r- en ce Do se (p er kg ), ro ut e No . o f ch il- dr en Ab so rp tio n co ns ta nt (p er h ) T m ax (m in ) C m ax (μ g/ m l) or C ss (μ g/ m l) Bi oa va ila bi lit y Cl ea ra nc e (m l/k g/ h) Ha lf lif e (m ) o r K e ( pe r h) AU C (μ g. m in /m l) M al no ur - is he d Eu tr op hi c M al no ur - is he d Eu tr op hi c M al no ur is he d Eu tr op hi c M al no ur - is he d Eu tr op hi c M al no ur - is he d Eu tr op hi c M al no ur - is he d Eu tr op hi c As ht on et a l. 19 93 41 25 g , I V 34 a – – – – – – M : 4 .8 K: 2 .9 * 5. 9 M t ½ : 3 .7 K t ½ : 4 .9 t ½ : 2 .4 M : 2 0. 4/ kg c K: 3 5. 9/ kg c * 11 .1 /k gc Sa m ot ra et a l. 19 86 42 50 g , or al 12 1. 0 1. 1 2. 1 2. 7 C m ax : 1 8 C m ax : 2 4 – – t ½ : 3 .4 * t ½ : 7 .0 12 8* 25 2 Er ik ss on et a l. 19 83 43 25 g , IV /o ra l 37 M : 2 .3 K: 3 .5 7 M K: 3 .9 6* 1. 86 M : 2 .3 K: 3 .5 7 M K: 3 .9 6* 1. 86 IV C m ax : K > M K > M > N b po C m ax : < 5 μg /m l K: 4 .1 6* M : 8 .1 6 M K: 5 .3 9 7. 53 K t ½ : 3 .7 6* M t ½ : 2 .8 8 M K t ½ : 3 .2 t ½ : 2 .8 5 K > M K > M > N Bi oa va il : M : 5 7% * K: 4 4% * M K: 3 0% * Bi oa va il: 85 % M eh ta et a l. 19 83 44 25 g , or al 13 0. 04 5* 1. 09 4. 0* 2. 0 C m ax : 2 0. 5 C m ax : 1 8. 3 – – t ½ : 6 .8 6* K e : 0 .1 09 * t ½ : 3 .3 K e : 0 .2 13 32 .9 9/ kg * 10 .4 3/ kg Sa in i et a l. 19 81 45 25 m g, IV 21 a – – M : 0 .2 5 K: 0 .2 5 0. 25 M C m ax : 1 0. 0* K C m ax : 1 1. 5* C m ax : 1 6. 9 M : 3 80 d K: 3 70 d 34 0d M t ½ : 1 .2 27 K t ½ : 1 .2 45 M K e: 0. 00 94 K K e : 0. 00 93 t ½ : 1 .3 2 K e : 0 .0 09 M : 3 8. 56 e K: 3 9. 50 e 38 .6 3e M eh ta et a l. 19 81 46 25 g x 8 do se s, IV /o ra l 21 a – – – – IV C SS p re -d os e 1 8. 0* IV C SS 2 h po st -d os e 24 .1 * po C SS p re -d os e 16 .6 * po C SS 2 h po st -d os e 23 .7 * 10 .0 19 .1 9. 7 16 .0 – – – – – – M eh ta et a l. 19 75 47 25 m g, or al 14 a – – 4. 0 2. 0 C m ax : 2 1. 3 C m ax : 1 7. 8 Ur in e (d ru g) at 3 0 h: 4 0 μg /m l* 10 0 μg /m l – – – – AU C, a re a un de r t he p la sm a co nc en tra tio n tim e cu rv e; C m ax , m ax im um c on ce nt ra tio n; C ss , s te ad y- st at e co nc en tra tio n; IV , i nt ra ve no us ; K , k w as hi or ko r; K e , e lim in at io n co ns ta nt ; M , m ar as m us ; M K, m ar as m ic k w as hi or ko r; N, n or m al (c on tro ls ); po , p er or al ; t ½ , h al f l ife ; T m ax , t im e to m ax im um c on ce nt ra tio n; U , u nd er w ei gh t; * P < 0 .0 5. a M al nu tri tio n gr ad es w er e de te rm in ed u si ng w ei gh t f or a ge , n ot w ei gh t f or h ei gh t. b A lth ou gh a ll su bt yp es o f m al nu tri tio n ha d le ve ls 5 –2 5 μg /m l f or 4 –9 h ou rs . c M in /m m ol u se d. d M l/m 2 /m in u se d. e L /g 2 u se d. 601Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished childrenMarzia Lazzerini & David Tickell occur (i.e. the minimum inhibitory con- centration [MIC] for common infecting organisms).30–32 Although not reported, the volume of distribution (i.e. the dis- tribution of a drug between plasma and the rest of the body) can be assumed from parenteral models given similar peak con- centrations, as described later in the text. Studies suggest that reduced renal blood flow and glomerular filtration rate in malnutrition lengthen drug half life and cause slow clearance.30,32,35 However, the side-effects of amoxicillin are pre- dominantly idiosyncratic, with minimal dose-related toxicity.24,25 Therefore, time above MIC is more important to thera- peutic efficacy than serum concentrations (“maximal dose” strategy).24 Cotrimoxazole Clinical safety and efficacy No studies were retrieved on cotrimoxa- zole as a first-line treatment for children with SAM. One ongoing study in Kenya is examining the use of cotrimoxazole as a prophylaxis against infections to reduce mortality in these children (trial identifier NCT00934492). Pharmacokinetics Two studies, both with a small sample size, were retrieved (Table 3).33,34 Cotri- moxazole has high oral bioavailability24,25 and differences between malnourished and eutrophic children in peak concen- trations or in time to Cmax were not sig- nificant.34 Malnourished and eutrophic children also showed similar volumes of distribution.34 According to limited data on sul- famethoxazole, malnutrition results in prolonged half life, a larger area under the plasma concentration curve (AUC) and non-significantly slower drug clearance.34 The AUC represents drug bioavailability in terms of plasma concentration as a function of time and indicates the potential for both thera- peutic effect and toxicity. Ampicillin and gentamicin Clinical safety and efficacy One before-and-after study (n = 300) reported on second-line antibiotics in children with SAM. The introduction of a standardized antibiotic regimen composed of ampicillin and gentamicin, together with an algorithm for hypogly- cemia management, reduced the case fatality rate from 20% to 6% (OR = 4; 95% CI: 1.7–9.8).28 Given the design of the study, it is not possible to estimate the relative effect of the introduction of the antibiotic treatment regimen alone. Pharmacokinetics Parenteral penicillin Three studies were retrieved (n = 47, n = 29 and n = 8 respectively ; Ta- ble 4).30,32,35 None found a significant dif- ference in Cmax when penicillins were de- livered intramuscularly to malnourished versus eutrophic individuals.30,32 A trend towards a lower volume of distribution was found in subjects with marasmus and marasmic kwashiorkor,30 with no signifi- cant changes noted between admission and recovery.35 There was no appreciable change in protein binding in the presence of malnutrition.33 Significantly slower clearance in all states of malnutrition was seen in one study,30 and a similar trend was seen in another.32 After nutritional rehabilitation a return to a shorter half life and to faster clearance was shown.35 Gentamicin Five studies were retrieved (Table 4).36–40 Gentamicin administered intramuscu- larly reached similar peak plasma con- centrations in malnourished children and eutrophic controls,36,37 but intravenous gentamicin resulted in lower plasma con- centrations in malnourished infants (ex- plained by a larger volume of distribution, with more drug moving into non-plasma tissues).39 Two studies showed a higher volume of distribution in malnourished children,36,39 and one found a low to nor- mal volume of distribution on admission and a rise with recovery.40 Gentamicin exhibits concentration- dependent activity and a “post-antibiotic effect” (i.e. persistent bactericidal activity even below the MIC). Thus, one daily dose instead of three can lower toxicity. Compared with traditional three times daily dosing, a single daily dose produced higher peak concentrations and lower 24-hour trough levels in malnourished children,38 with values comparable to those seen in well nourished children.24,49 Gentamicin nephrotoxicity and ototoxicity result from prolonged serum levels > 2 μg/ml,24,25 largely reflecting AUC and clearance, so monitoring se- rum levels is recommended. However, clearance appears largely unaffected by malnutrition36,37,39 (except for prolonged clearance in shock and renal impair- ment),36 although one small study found delayed clearance and half life, which im- proved with rehabilitation.40 There were no reports of differences in AUC between groups37,39 or of an increase in adverse events with high peak concentrations.24 Chloramphenicol Clinical safety and efficacy One RCT (n = 144) was retrieved. In chil- dren with SAM complicated by clinical and radiological pneumonia, the number of children recovering, treatment failures or deaths was the same in children treated with oral chloramphenicol and with cotri- moxazole. This trial was conducted from 1990–92 in a context of low resistance to cotrimoxazole and low HIV prevalence. 21 Pharmacokinetics Seven original studies41–47 (Table 5) and one review48 were found. Oral admin- istration studies demonstrate variable absorption and peak concentrations in malnourished subjects.42–44,47 All studies of intravenous administration but one show higher peak concentrations in malnourished subjects than in eutrophic controls43,45,46 No studies looked at intra- muscular administration. With multiple oral or intravenous doses, steady-states were significantly higher in malnour- ished children versus controls.46 Studies found no significant change in volume of distribution41,43 or protein binding33,44 in malnourished subjects. Several studies show significantly slower clearance and/or a longer half life leading to higher AUC,41,43,44,47 mostly owing to poor hepatic conjugation result- ing from malnutrition.41 In contrast, two weaker studies found faster elimination kinetics in malnourished subjects.42,45 Many pharmacokinetic abnormalities re- solved with nutritional rehabilitation.44,47 Although some adverse events are idio- syncratic,24 data suggest concentrations > 25–30 μg/ml may precipitate toxicity, including bone marrow suppression.24,25,41 A review therefore concluded that a reduced dose of chloramphenicol would be warranted in malnourished subjects,48 a view supported by multiple studies find- ing higher drug concentrations42–44,46,47 and delayed elimination in the presence of malnutrition.41,43,44,47 Ceftriaxone No published studies were retrieved for ceftriaxone. One ongoing trial is examin- ing the use of ceftriaxone in children with 602 Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished children Marzia Lazzerini & David Tickell SAM and pneumonia (trial identifier NCT00968370). Ciprofloxacin No studies were retrieved for cipro- floxacin. One ongoing trial is looking at oral absorption of ciprofloxacin in children with SAM (trial identifier IS- RCTN31079753). All other antibiotics Clinical safety and efficacy One personal communication about a retrospective review of case notes was retrieved. In children with SAM admit- ted to therapeutic feeding centres, a significant association was found between mortality ratio (i.e. observed mortal- ity divided by expected mortality using the Prudhon Index)50 and the use of an antibiotic upon admission (r2 = 0.37; P = 0.002). Other aspects of care were not controlled for rigorously.29 Discussion This review highlights the lack of good quality clinical studies on the use of antibiotics in severely malnourished children. Of the few pharmacokinetic studies that exist, most use single dose kinetics and rarely correlate findings with clinical outcomes, limiting conclusions. Most of them have also excluded severely compromised children, which limits the generalizability of the findings. Given these limitations, the following conclu- sions can be drawn. First-line antibiotics Whether antibiotics should be given routinely to children with uncomplicated SAM undergoing outpatient treatment remains undetermined. Epidemiological data on the risk of infection in these chil- dren are lacking. The good clinical condi- tion and low case fatality rates reported in these children,5 together with the findings of one retrospective study,26 suggest that these children have a low risk of bacterial infections. However, the risk of infection differs in subgroups of children, such as those who are HIV-infected. Data on HIV+ malnourished children, although inconsistent, suggest that they suffer more frequent episodes of severe pneumonia and diarrhoea10,51 and have higher rates of death from bacteraemia.11,51 Cotrimoxazole remains questionable as first-line therapy in HIV+ children al- ready receiving the drug for Pneumocystis jeroveci (carinii) pneumonia prophylaxis, and efficacy may also be affected by antibi- otic resistance patterns in many settings. Amoxicillin remains a valuable option, since it has been proven as efficacious as ceftriaxone but cheaper. Pharmacokinetic studies support the use of oral penicillin in children with SAM at the same doses used for eutrophic children unless severe malabsorption or diarrhoea are present. Taking the drug during fasting can in- crease absorption. No further data are available to guide recommendations surrounding the use of first-line antibiotics. Whether first line antibiotics are appropriate for hospitalized children, who by definition have complicated SAM, remains to be determined. An alternative would be to automatically consider these children for a “second-line” regimen. Second-line antibiotics Based on epidemiological data,9–23 recom- mending broad-spectrum antibiotics for children with complicated SAM appears reasonable. Only one retrospective study reported on the use of ampicillin and gentamicin, whose use led to lower case fatality rates than a previous non-standard protocol. Pharmacokinetic data suggest that parenteral penicillin and gentami- cin can be safely given to malnourished children at the doses and intervals recom- mended for non-malnourished children, unless renal failure or shock are present. The comparative efficacy and safety of other parenteral antibiotics have not been studied. Moreover, high rates of in vitro resistance to ampicillin and gentami- cin have been reported in several African countries (Table 1).9–23 According to dis- cussions with staff members, institutions for the care of malnourished children vary in the degree to which they follow current recommendations. Many institutions are now giving more potent broad-spectrum antibiotics to hospitalized malnourished children guided largely by local in vitro sensitivity data. Third-line antibiotics Only one small RCT reported equivalent efficacy for cotrimoxazole and oral chlor- amphenicol in children with pneumonia, albeit with limited generalizability.21 Moreover, pharmacokinetic studies sug- gest that oral chloramphenicol is errati- cally absorbed in malnourished children and that parenteral administration is preferable. Given the risk of accumulation and potential toxicity, adjusting the dose or the frequency is recommended until further data on safety become available. Other third-line antibiotics often used in practice include ceftriaxone and ciprofloxacin. No studies have been published on the efficacy, safety or phar- macokinetics of these drugs in children with SAM. Ceftriaxone has a broad spectrum, is given in a single daily dose intravenously or intramuscularly and has a wide therapeutic window that increases its likely safety. Reducing its dose or fre- quency is advisable in children with severe renal compromise. Ciprofloxacin remains a promising treatment considering its broad spectrum, good oral bioavailability and low reported resistance rates. These two drugs are often costly, although their prices have decreased in the recent past, and both are already available and widely used in many low- and middle-income regions. Data on the efficacy and safety of these antibiotics in children with SAM are urgently needed. Summary and recommendations The use of broad-spectrum antibiotics for children with SAM is supported by epidemiological data demonstrating a high prevalence of infections in these children, but clinical studies are lacking. Evidence supports the use of amoxicillin as a first-line treatment option. However, in children with uncomplicated SAM who are undergoing outpatient manage- ment, whether routine antibiotics infer an extra benefit is unclear. Ampicillin and gentamicin, as rec- ommended by current WHO guidelines, are the only second-line antibiotics that have been studied in controlled tri- als. There is support from low-quality evidence for their use in hospitalized children with SAM. Global recommendations for an- tibiotic treatment in children with malnutrition cannot be further clarified at present because there are few ongoing clinical and pharmacokinetic trials. Local patterns of susceptibility to antibiotics should be taken into account in the choice of an antibiotic. Well designed RCTs are required to further address doubts surrounding the routine use of antibiotics in uncompli- cated SAM, with stratification for HIV status. Also needed are multicentre, multiarm RCTs to further assess the ef- ficacy and safety of different antibiotic regimens for complicated SAM and to 517480.01.TLB/1742.01:iod | 606–395:98;1102 nagrO htlaeH dlroW lluB306 sweiver citametsyS llekciT divaD & inirezzaL aizraMnerdlihc dehsiruonlam ylereves ni scitoibitnA htiw atad ytivitisnes ortiv ni erapmoc rof noitacfiitarts htiw ,semoctuo lacinilc no seiduts citenikocamrahP .sutats VIH nicaxoflorpic dna enoxairftec fo esu eht yltnegru osla era nerdlihc dehsiruonlam ni dna ytilibaliava desaercni eht nevig dedeen .sgnittes ynam ni scitoibitna eseht fo esu -ilpmoc htiw nerdlihc ,yldettimdA esuaceb yduts ot tlucffiid era MAS detac -atneserp gninetaerht-efil evah nefto yeht tnemeganam detecaf-itlum rieht dna snoit kcaL .selbairav gnidnuofnoc ynam secudorp -sys siTh .seiduts stimil rehtruf secruoser fo lacinilc erom taht nwohs sah weiver citamet dedeen ylraelc era slairt citenikocamrahp dna -liava tseb eht htiw nerdlihc eseht edivorp ot ■ .erac desab-ecnedive elba stnemegdelwonkcA -epS noitamrofnI ,ejtuL airottiV knaht eW ,puorG sesaesiD suoitcefnI enarhcoC ,tsilaic .enicideM laciporT fo loohcS loopreviL troper lacinhcet lanigiro eTh :gnidnuF dednuf saw sevired krow siht hcihw morf dna senicideM laitnessE ,OHW eht yb .aveneG ,seiciloP lacituecamrahP .deralced enoN :stseretni gnitepmoC ملخص المضادات الحيوية في الأطفال الذين يعانون من سوء التغذية الوخيم: مراجعة منهجية للنجاعة، والسلامة، والحرائك الدوائية الغرض مراجعة منهجية للبّينات الداعمة للدلائل الإرشادية لمنظمة الصحة العالمية التي توصي بوصف المضادات الحيوية واسعة الطيف للأطفال الذين يعانون من سوءة التغذية الحاد الوخيم. الطريقة جرى البحث في قواعد المعطيات التالية: سنترال LARTNEC، وميدلاين ENILDEM، وإيمباز ESABME، وليلاكس SCALIL، وبوب لاين ENILPOP، وكاب BAC عن الملخصات المنشورة وسجلات التجارب الجارية، كما أجريت اتصالات بالخبراء في هذا الصدد، وجرى البحث يدويا ً عن تدوين جلسات المؤتمرات وقوائم المراجع. وقد أدرج في المراجعة جميع أنواع الدراسات عدا التبليغ عن الحالة. النتائج اكُتِشَفت تجربتان عشوائيتان ُمضبطتان، إحداهما تجربة لقبل-وبعد العلاج، واكتشف تقريران استعاديان حول النجاعة والسلامة السريرية، وكذلك 81 دراسة عن الحرائك الدوائية. كانت جودة التجارب سيئة على نحو عام، ولم يمكن تجميع النتائج بسبب التغايرية. كان الأموكساسيللين الفموي لمدة 5 أيام فعالاً بنفس درجة سيفترياكسون العضلي لمدة يومين (في إحدى التجربتين العشوائيتين المضبطتين). أما بخصوص سوء التغذية الحاد الوخيم، فقد تبين أن الأموكساسيللين لم يكن له جدوى وذلك مقارنة بالُغفل (في إحدى الدراستين الاستعاديتين). وقد أدى إدخال نظام معياري باستخدام الأمبيسيللين والجنتاميسين إلى تقليل الوفيات على نحو ُيعَتد به في الأطفال المعالجين في المستشفيات (نسبة الأرجحية: 0.4؛ وفاصلة الثقة %59: 7.1- 8.9؛ في الدراسة المجراة قبل-وبعد العلاج). كان الكلورمفنيكول الفموي فعالاً بنفس درجة التريميثوبريم-سلفاميثوكسازول في الأطفال الذين كانوا يعانون من الالتهاب الرئوي (في إحدى التجربتين العشوائيتين المضبطتين). ودلت المعطيات حول الحرائك الدوائية أن الجرعات الطبيعية من البنسيللين، والكوتريموكسازول والجنتاميسين جرعات آمنة في الأطفال الذين يعانون من سوء التغذية، بينما تحتاج جرعة الكلورمفنيكول وتكرارها إلى الضبط. ولا تكفي البّينات الموجودة لتوضيح المزيد من التوصيات الخاصة بالعلاج بالمضادات الحيوية في الأطفال الذين يعانون من سوء التغذية الحاد الوخيم. الاستنتاج هناك حاجة إلى تجارب عشوائية ُمضبطة واسعة النطاق لتحديد العلاج المثالي بالمضادات الحيوية للأطفال الذين يعانون من سوء التغذية الحاد الوخيم مع وجود أو عدم وجود المضاعفات. كما أن هناك حاجة إلى المزيد من البحث حول سمّية الجنتاميسين والكلورمفنيكول وحول الحرائك الدوائية للسيفترياكسون والسيبروفلوكساسين. 要摘 价评统系学力动物药和性全安、效功:素生抗用应童儿良不养营重严对 的荐推南指织组生卫界世为,据证关相价评统系在旨 的目 提素生抗谱广用应童儿的)MAS(良不养营性急重严有患对 。持支供 验 试 照 对 床 临 e n a r h c o C ( L A R T N E C 索 检 法 方 和 析 分 献 文 学 医 机 联 ( E N I L D E M 、 ) 库 册 注 心 中 据数SCALIL、)摘文学医兰荷(ESABME、)统系索检 在正及以库据数stcartsbA BAC和库据数ENILPOP、库 和料资议会的关相索检工手,家专系联。验试册注的行进 括包均型类究研有所的外以告报例案个单除。料资考参 。中价评本在 验试照对机随个两的关相性全安和效功床临与到索检 果结 药个81及以,告报性顾回个两、究研照对后前个一、)TCR( 将法无,系关性质异于由,高不遍普量质验试。究研学力动物 曲孢头射注肉肌于同等效功的天5林西莫阿服口。集汇果结 ,良不养营性急重严的单简于对。)验试照对机随个1(天2松 性顾回个1(效疗的好更出示显剂照对效无比未并林西莫阿 住了低降大大入引的方配准标素霉大庆和林西比氨。)究研 个1;8.9-7.1:lC间区信置%59;0.4:RO比势优(率亡死的童儿院 于同等效功的素霉氯服口童儿的炎肺染感。)究研照对后前 量剂常正,明表据数学力动物药。)验试照对机随个1(制特菌 儿的良不养营于对素霉大庆和唑恶甲胺磺方复、素霉青的 证有现。整调要需率频用服或量剂的素霉氯而,的全安是童 采童儿的良不养营性急重严有患对明阐步一进以足不还据 。议建的疗治素生抗用 性急重严有患对定确来验试照对机随型大施实要需 论结 所)童儿的症发并无及以症发并有伴括包(童儿的良不养营 霉氯和素霉大庆对要需还。案方疗治素生抗佳最的取采 一进做学力动物药的星沙丙环和松曲孢头及以性毒的素 。究研的步 604 Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished children Marzia Lazzerini & David Tickell Résumé Antibiotiques chez les enfants gravement dénutris: évaluation systématique de l’efficacité, de la sécurité et de la pharmacocinétique Objectif Évaluer de façon systématique la preuve de l’application des directives de l’Organisation mondiale de la Santé recommandant les antibiotiques à large spectre chez les enfants présentant une malnutrition aiguë sévère (MAS). Méthodes Les recherches ont été réalisées dans les registres des essais CENTRAL, MEDLINE, EMBASE, LILACS, POPLINE, CAB Abstracts, ainsi que dans d’autres registres d’essais en cours. Des experts ont été contactés. Des recherches ont également été effectuées manuellement sur des listes de référence et des comptes rendus de conférence. Tous les types d’étude, à l’exception des rapports de cas uniques, ont été inclus. Résultats Deux essais contrôlés randomisés (ECR), une étude avant/après et deux rapports rétrospectifs sur l’efficacité et la sécurité cliniques ont été récupérés, avec 18 études pharmacocinétiques. La qualité des essais était généralement médiocre et les résultats n’ont pas pu être mis en commun à cause de leur hétérogénéité. L’amoxicilline orale pendant 5 jours était aussi efficace que la ceftriaxone intramusculaire pendant 2 jours (1 ECR). Pour la MAS sans complication, l’amoxicilline n’a montré aucun avantage par rapport à un placebo (1 étude rétrospective). L’introduction d’un régime normalisé utilisant l’ampicilline et la gentamicine a considérablement réduit la mortalité chez les enfants hospitalisés (rapport des cotes, RC: 4.0; intervalle de confiance de 95%, IC: 1,7–9,8; 1 étude avant/ après). Le chloramphénicol oral était aussi efficace que le triméthoprime- sulfaméthoxazole chez les enfants souffrant de pneumonie (1 ECR). Les données pharmacocinétiques suggèrent que des doses normales de pénicilline, de cotrimoxazole et de gentamicine sont sans danger chez les enfants souffrant de malnutrition, alors que la dose ou la fréquence du chloramphénicol nécessite un ajustement. Les preuves existantes ne sont pas assez solides pour clarifier davantage les recommandations en matière de traitement antibiotique chez les enfants souffrant de MAS. Conclusion De grands ECR sont nécessaires afin de définir le traitement antibiotique optimal chez les enfants souffrant de MAS avec ou sans complications. Des recherches supplémentaires dans la toxicité de la gentamicine et du chloramphénicol et dans la pharmacocinétique de la ceftriaxone et de la ciprofloxacine sont également requises. Резюме Применение антибиотиков при лечении детей, страдающих тяжелой острой недостаточностью питания: систематический обзор эффективности, безопасности и фармакокинетики Цель Провести систематический обзор данных в поддержку разработанного Всемирной организацией здравоохранения руководства, рекомендующего применение широкого спектра антибиотиков при лечении детей, страдающих тяжелой острой недостаточностью питания (ТОНП). Методы Был проведен поиск по резюме в базах данных CENTRAL, MEDLINE, EMBASE, LILACS, POPLINE, CAB, а также по регистрам текущих клинических испытаний; организованы контакты со специалистами; просмотрены материалы конференций и рекомендательные списки научных работ. Поиском были охвачены все виды исследований, кроме описаний единичных случаев. Результаты Были выявлены два рандомизированных контролируемых испытания (РКТ), одно исследование «до – после» и два ре троспективных отче та о клинической эффективности и безопасности, а также 18 фармакокинетических исследований. Качество испытаний было в целом низким, а результаты нельзя было обобщить ввиду их разнородности. Эффект от перорального приема амоксициллина в течение пяти дней был таким же, как от внутримышечного введения цефтриаксона в течение двух дней (одно РКТ). Для ТОНП без осложнений какого-либо преимущества амоксициллинa перед плацебо не наблюдалось (одно ретроспективное исследование). Применение стандартной схемы с использованием амплициллина и гентамицина привело к значительному снижению смертности среди госпитализированных детей (отношение шансов, ОШ: 4,0; 95% доверительный интервал, ДИ: 1,7–9,8; одно исследование «до – после»). У детей с пневмонией пероральный прием хлорамфеникола дал такой же результат, что и прием триметоприма–сульфометоксазола (одно РКТ). Данные фармакокинетических исследований позволяют сделать вывод, что нормальные дозы пенициллина, котримоксазола и гентамицина безопасны для детей с недостаточностью питания, тогда как дозировка и частота приема хлорамфеникола требуют коррекции. Имеющиеся данные недостаточно убедительны, чтобы на их основе можно было уточнить рекомендации по применению антибиотиков для лечения детей с ТОНП. Вывод Для определения оптимальной схемы применения антибиотиков при лечении детей, страдающих ТОНП, с осложнениями и без осложнений нужны более масштабные РКТ. Кроме того, необходимо провести дальнейшие исследования токсичности гентамицина и хлорамфеникола, а также фармакокинетики цефтриаксона и ципрофлоксацина. Resumen Antibióticos en niños con desnutrición grave: revisión sistemática de su eficacia, seguridad y farmacocinética Objetivo Revisar sistemáticamente los datos que apoyan las directrices de la Organización Mundial de la Salud que recomiendan la administración de antibióticos de amplio espectro en niños con desnutrición grave (NDG). Métodos Se realizó una búsqueda en los resúmenes CENTRAL, MEDLINE, EMBASE, LILACS, POPLINE, CAB y en los registros de ensayos en marcha. Nos pusimos en contacto con expertos en la materia. Se realizaron búsquedas manuales en listas de referencia y en actas de congresos. Se incluyeron todo tipo de estudios, excepto los informes de casos clínicos individuales. Resultados Se recuperaron dos ensayos controlados aleatorizados (ECA), un estudio comparativo del antes y el después y dos informes retrospectivos sobre eficacia clínica y seguridad, junto con 18 estudios de farmacocinética. La calidad del ensayo fue generalmente baja y los resultados no se pudieron agrupar debido a su heterogeneidad. El 605Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished childrenMarzia Lazzerini & David Tickell tratamiento con amoxicilina por vía oral durante 5 días resultó ser tan efectivo como la ceftriaxona intramuscular durante 2 días (1 ECA). La amoxicilina no superó los beneficios de un placebo para el tratamiento de niños con desnutrición grave que no presentaban otras complicaciones (1 estudio retrospectivo). La introducción de un tratamiento estandarizado con ampicilina y gentamicina redujo de manera significativa la mortalidad entre los niños hospitalizados (oportunidad relativa, OR: 4,0; intervalo de confianza del 95%, IC: 1,7–9,8; 1 estudio comparativo del antes y el después). El tratamiento con cloranfenicol por vía oral resultó ser tan efectivo como la combinación de trimetoprima y sulfametoxazol en el tratamiento de niños con neumonía (1 ECA). Los datos de farmacocinética sugieren que las dosis normales de penicilinas, asociación de trimetroprim y sulfametoxazol y gentamicina resultan seguras en niños malnutridos, mientras que, en el caso del cloranfenicol, deberían ajustarse las dosis o la frecuencia de administración. Las evidencias existentes no son lo suficientemente sólidas para aclarar más las recomendaciones sobre tratamientos de antibióticos en niños con desnutrición grave. Conclusión Es necesario realizar amplios ECA para definir el tratamiento óptimo con antibióticos de los niños con desnutrición grave con y sin complicaciones. También es necesario investigar mejor la toxicidad de la gentamicina y el cloranfenicol y la farmacocinética de la deftriaxona y de la ciprofloxacina. References 1. Black RE, Allen LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M et al.; Maternal and Child Undernutrition Study Group. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008;371:243–60. doi:10.1016/S0140-6736(07)61690-0 PMID:18207566 2. Management of severe malnutrition: a manual for physicians and other senior health care workers. Geneva: World Health Organization; 1999. 3. Pocketbook of hospital care for children: guidelines for the management of common illnesses with limited resources. Geneva: World Health Organization; 2005 4. Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, Giugliani E et al.; Maternal and Child Undernutrition Study Group. What works? Interventions for maternal and child undernutrition and survival. Lancet 2008;371:417–40. doi:10.1016/S0140-6736(07)61693-6 PMID:18206226 5. Community based management of severe acute malnutrition: a joint statement. Geneva: World Health Organization & World Food Programme & United Nations System Standing Committee on Nutrition & United Nations Children’s Fund; 2007. Available from: http://www.who.int/nutrition/ publications/severemalnutrition/en/index.html [accessed 17 April 2011]. 6. Ashworth A, Chopra M, McCoy D, Sanders D, Jackson D, Karaolis N et al. WHO guidelines for management of severe malnutrition in rural South African hospitals: effect on case fatality and the influence of operational factors. Lancet 2004;363:1110–5. doi:10.1016/S0140-6736(04)15894-7 PMID:15064029 7. Puoane T, Cuming K, Sanders D, Ashworth A. Why do some hospitals achieve better care of severely malnourished children than others? Five-year follow-up of rural hospitals in Eastern Cape, South Africa. Health Policy Plan 2008;23:428–37. doi:10.1093/heapol/czn036 PMID:18796499 8. Fergusson P, Tomkins A. HIV prevalence and mortality among children undergoing treatment for severe acute malnutrition in sub-Saharan Africa: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg 2009;103:541–8. doi:10.1016/j.trstmh.2008.10.029 PMID:19058824 9. Sunguya BF, Koola JI, Atkinson S. Infections associated with severe malnutrition among hospitalised children in East Africa. Tanzan Health Res Bull 2006;8:189–92. PMID:18254514 10. Bachou H, Tylleskär T, Kaddu-Mulindwa DH, Tumwine JK. Bacteraemia among severely malnourished children infected and uninfected with the human immunodeficiency virus-1 in Kampala, Uganda. BMC Infect Dis 2006;6:160. doi:10.1186/1471-2334-6-160 PMID:17090299 11. Bachou H, Tylleskär T, Downing R, Tumwine JK. Severe malnutrition with and without HIV-1 infection in hospitalised children in Kampala, Uganda: differences in clinical features, haematological findings and CD4+ cell counts. Nutr J 2006;5:27. doi:10.1186/1475-2891-5-27 PMID:17042940 12. Babirekere-Iriso E, Musoke P, Kekitiinwa A. Bacteraemia in severely malnourished children in an HIV-endemic setting. Ann Trop Paediatr 2006;26:319–28. doi:10.1179/146532806X152845 PMID:17132297 13. Noorani N, Macharia WM, Oyatsi D, Revathi G. Bacterial isolates in severely malnourished children at Kenyatta National Hospital, Nairobi. East Afr Med J 2005;82:343–8. PMID:16167706 14. Rabasa AI, Shattima D. Urinary tract infection in severely malnourished children at the University of Maiduguri Teaching Hospital. J Trop Pediatr 2002;48:359–61. doi:10.1093/tropej/48.6.359 PMID:12521279 15. Bahwere P, Levy J, Hennart P, Donnen P, Lomoyo W, Dramaix-Wilmet M et al. Community-acquired bacteremia among hospitalized children in rural central Africa. Int J Infect Dis 2001;5:180–8. doi:10.1016/S1201-9712(01)90067-0 PMID:11953214 16. Thame M, Stephen C, Wilks R, Forrester TE. The appropriateness of the current antibiotic empiric therapy based on the bacteria isolated from severely malnourished Jamaican children. West Indian Med J 2001;50:140– 3. PMID:11677912 17. Manary MJ, Brewster DR. Intensive nursing care of kwashiorkor in Malawi. Acta Paediatr 2000;89:203–7. doi:10.1111/j.1651-2227.2000.tb01217.x PMID:10709892 18. Çaksen H, Cesur Y, Uner A, Arslan S, Sar S, Celebi V et al. Urinary tract infection and antibiotic susceptibility in malnourished children. Int Urol Nephrol 2000;32:245–7. doi:10.1023/A:1007104326689 PMID:11229640 19. Reed RP, Wegerhoff FO, Rothberg AD. Bacteraemia in malnourished rural African children. Ann Trop Paediatr 1996;16:61–8. PMID:8787368 20. Reed RP, Wegerhoff FO. Urinary tract infection in malnourished rural African children. Ann Trop Paediatr 1995;15:21–6. PMID:7598432 21. Mulholland EK, Falade AG, Corrah PT, Omosigho C, N’Jai P, Giadom B et al. A randomized trial of chloramphenicol vs. trimethoprim-sulfamethoxazole for the treatment of malnourished children with community-acquired pneumonia. Pediatr Infect Dis J 1995;14:959–65. doi:10.1097/00006454-199511000- 00007 PMID:8584362 22. Kala UK, Jacobs DW. Evaluation of urinary tract infection in malnourished black children. Ann Trop Paediatr 1992;12:75–81. PMID:1376591 23. Isaack H, Mbise RL, Hirji KF. Nosocomial bacterial infections among children with severe protein energy malnutrition. East Afr Med J 1992;69:433–6. PMID:1396209 24. Goodman S, Gilman A. 11th ed. The pharmacological basis of therapeutics, ed. Brunton LL, Lazo JS, Parker KL, editors. New York: McGraw-Hill; 1975. 25. Thomson Reuters Micromedex® 1, 1974-2009 [Internet]. Available from: http://www.micromedex.com/pressroom/ [accessed 17 April 2011]. 26. Trehan I, Amthor RE, Maleta K, Manary MJ. Evaluation of the routine use of amoxicillin as part of the home-based treatment of severe acute malnutrition. Trop Med Int Health 2010;15:1022–8. PMID:20545919 27. Dubray C, Ibrahim SA, Abdelmutalib M, Guerin PJ, Dantoine F, Belanger F et al. Treatment of severe malnutrition with 2-day intramuscular ceftriaxone vs 5-day amoxicillin. Ann Trop Paediatr 2008;28:13–22. doi:10.1179/146532808X270635 PMID:18318945 28. Wilkinson D, Scrace M, Boyd N. Reduction in in-hospital mortality of children with malnutrition. J Trop Pediatr 1996;42:114–5. doi:10.1093/ tropej/42.2.114 PMID:8984207 29. Golden BE, Corbett M, McBurney R, Golden MH. Malnutrition: trials and triumphs. Trans R Soc Trop Med Hyg 2000;94:12–3. doi:10.1016/S0035- 9203(00)90420-6 PMID:10748888 30. Bolme P, Eriksson M, Paalzow L, Stintzing G, Zerihun G, Woldemariam T. Malnutrition and pharmacokinetics of penicillin in Ethiopian children. Pharmacol Toxicol 1995;76:259–62. doi:10.1111/j.1600-0773.1995. tb00140.x PMID:7617556 31. Zerihun G, Ashton M, Eriksson M. Oral absorption of amoxicillin in Ethiopian children with respiratory symptoms and different nutritional status. Acta Paediatr Scand 1991;80:972–4. doi:10.1111/j.1651-2227.1991.tb11765.x PMID:1755309 606 Bull World Health Organ 2011;89:593–606 | doi:10.2471/BLT.10.084715 Systematic reviews Antibiotics in severely malnourished children Marzia Lazzerini & David Tickell 32. Bolme P, Gebre-Ab T, Hadgu P, Meeuwisse G, Stintzing G. Absorption and elimination of penicillin in children with malnutrition. Ethiop Med J 1980;18:151–7. PMID:6780336 33. Buchanan N. Drug-protein binding and protein energy malnutrition. S Afr Med J 1977;52:733–7. PMID:601647 34. Bravo IG, Bravo ME, Plate G, Merlez J, Arancibia A. The pharmacokinetics of cotrimoxazole sulphonamide in malnourished (marasmic) infants. Pediatr Pharmacol (New York) 1984;4:167–76. PMID:6436778 35. Buchanan N, Robinson R, Koornhof HJ, Eyberg C. Penicillin pharmacokinetics in kwashiorkor. Am J Clin Nutr 1979;32:2233–6. PMID:495540 36. Seaton C, Ignas J, Muchohi S, Kokwaro G, Maitland K, Thomson AH. Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition. J Antimicrob Chemother 2007;59:681–9. doi:10.1093/jac/dkl561 PMID:17347177 37. Samotra K, Gupte S, Raina RK. Pharmacokinetics of gentamicin in protein- energy malnutrition. Eur J Clin Pharmacol 1985;29:255–6. doi:10.1007/ BF00547433 PMID:3935465 38. Khan AM, Ahmed T, Alam NH, Chowdhury AK, Fuchs GJ. Extended-interval gentamicin administration in malnourished children. J Trop Pediatr 2006;52:179–84. doi:10.1093/tropej/fmi085 PMID:16126804 39. Bravo ME, Arancibia A, Jarpa S, Carpentier PM, Jahn AN. Pharmacokinetics of gentamicin in malnourished infants. Eur J Clin Pharmacol 1982;21:499–504. doi:10.1007/BF00542045 PMID:6176455 40. Buchanan N, Davis MD, Eyberg C. Gentamicin pharmacokinetics in kwashiorkor. Br J Clin Pharmacol 1979;8:451–3. PMID:508549 41. Ashton M, Bolme P, Alemayehu E, Eriksson M, Paalzow L. Decreased chloramphenicol clearance in malnourished Ethiopian children. Eur J Clin Pharmacol 1993;45:181–6. doi:10.1007/BF00315503 PMID:8223842 42. Samotra K, Gupte S, Raina RK. Effect of malnutrition on chloramphenicol kinetics in Indian children. Zhongguo Yao Li Xue Bao 1986;7:162–4. [Acta Pharm Sinica] PMID:2946157 43. Eriksson M, Paalzow L, Bolme P, Mariam TW. Chloramphenicol pharmacokinetics in Ethiopian children of differing nutritional status. Eur J Clin Pharmacol 1983;24:819–23. doi:10.1007/BF00607094 PMID:6411480 44. Mahta S, Nain CK, Kalsi HK, Mathur VS. Bioavailability and pharmacokinetics of chloramphenicol palmitate in malnourished children. Indian J Med Res 1981;74:244–50. PMID:6796509 45. Saini G, Mittal SK, Tayal G, Saini L. Chloramphenicol kinetics in malnutrition. Indian Pediatr 1981;18:805–10. PMID:7341474 46. Mehta S, Nain CK, Sharma B, Mathur VS. Steady state of chloramphenicol in malnourished children. Indian J Med Res 1981;73:538–42. PMID:7262924 47. Mehta S, Kalsi HK, Jayaraman S, Mathur VS. Chloramphenicol metabolism in children with protein-calorie malnutrition. Am J Clin Nutr 1975;28:977–81. PMID:808955 48. Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther 1990;15:159–65. PMID:2129200 49. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta- analysis. Pediatrics 2004;114:e111–8. doi:10.1542/peds.114.1.e111 PMID:15231982 50. Prudhon C, Golden MH, Briend A, Mary JY. A model to standardise mortality of severely malnourished children using nutritional status on admission to therapeutic feeding centres. Eur J Clin Nutr 1997;51:771–7. doi:10.1038/ sj.ejcn.1600483 PMID:9368812 51. Thuo N, Maitland K, Talbert A, Karisa J, Atkinson S, Berkley JA. HIV and SAM at Kilifi District Hospital, Kenya 2005 to 2008. Presented at the 10th CAPGAN Conference on Diarrhoea and Malnutrition, Blantyre, Malawi, 12–16 August 2009.